1. Home
  2. SOWG vs MBIO Comparison

SOWG vs MBIO Comparison

Compare SOWG & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sow Good Inc.

SOWG

Sow Good Inc.

HOLD

Current Price

$0.38

Market Cap

5.1M

ML Signal

HOLD

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.73

Market Cap

5.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOWG
MBIO
Founded
2010
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1M
5.8M
IPO Year
2011
2023

Fundamental Metrics

Financial Performance
Metric
SOWG
MBIO
Price
$0.38
$0.73
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.6M
28.6K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.99
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.81
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.53
52 Week High
$2.12
$7.00

Technical Indicators

Market Signals
Indicator
SOWG
MBIO
Relative Strength Index (RSI) 43.58 32.28
Support Level $0.38 $0.71
Resistance Level $0.58 $1.00
Average True Range (ATR) 0.05 0.05
MACD -0.00 -0.00
Stochastic Oscillator 18.60 3.71

Price Performance

Historical Comparison
SOWG
MBIO

About SOWG Sow Good Inc.

Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: